204 related articles for article (PubMed ID: 24890561)
1. Pharmacovigilance in practice: erythropoiesis-stimulating agents.
Hedenus M; Ludwig H; Henry DH; Gasal E
Cancer Med; 2014 Oct; 3(5):1416-29. PubMed ID: 24890561
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
3. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
4. Update on safety of ESAs in cancer-induced anemia.
Glaspy J
J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
[TBL] [Abstract][Full Text] [Related]
5. Management of anemia in cancer patients.
Calabrich A; Katz A
Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
[TBL] [Abstract][Full Text] [Related]
6. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A
Blood Adv; 2019 Apr; 3(8):1197-1210. PubMed ID: 30971397
[TBL] [Abstract][Full Text] [Related]
7. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
8. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
9. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
11. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
Tonia T; Bohlius J
Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
[TBL] [Abstract][Full Text] [Related]
12. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
13. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I; Vansteenkiste J
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
[TBL] [Abstract][Full Text] [Related]
15. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.
Aapro M; Jelkmann W; Constantinescu SN; Leyland-Jones B
Br J Cancer; 2012 Mar; 106(7):1249-58. PubMed ID: 22395661
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of chemotherapy-induced anemia].
Kadokura G; Katsumata N
Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey.
Cortinovis D; Beretta G; Piazza E; Luchena G; Aglione S; Bertolini A; Buzzoni R; Cabiddu M; Carnaghi C; Danova M; Farina G; Ferrari V; Frascaroli M; Reni M; Tansini G;
Tumori; 2013; 99(1):45-50. PubMed ID: 23548999
[TBL] [Abstract][Full Text] [Related]
18. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
Gebara SN; Moubayed H
J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
20. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
Bohlius J; Tonia T; Schwarzer G
Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]